Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.
Ondine Biomedical Inc. has announced the grant of 300,000 options to a key consultant, allowing them to subscribe for new common shares at an exercise price of 15.50 pence. These options will vest over three years and can be exercised within eight years, contributing to a total of 18,863,334 options outstanding, which represents 3.64% of the company’s current issued share capital.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, also known as photodisinfection. The company has a range of investigational products based on its proprietary technology, including a nasal photodisinfection system that is approved in Canada, Europe, and other countries under the name Steriwave®. Ondine is also pursuing regulatory approval in the US, where it has received special designations from the FDA.
Average Trading Volume: 390,174
Technical Sentiment Signal: Buy
Current Market Cap: £80.35M
See more data about OBI stock on TipRanks’ Stock Analysis page.